Details of Disease

Disease Name

Neurological disorder

Disease Class

6B60: Dissociative neurological symptom disorder

Disease Hierarchy

DIS01GPL: Grass pollen hypersensitivity

DISCFBRD: Neurological disorder

ICD-11

ICD-11: 6B60

Expand ICD-9

338,338.2,410,782.3,780

Disease Identifiers

MONDO ID

MONDO_0005071

MESH ID

D009422

UMLS CUI

C0027765

MedGen ID

14336

SNOMED CT ID

118940003

General Information of Disease (ID: DISCFBRD)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 4 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
GM-CSF	DMVJALH	Approved	NA	[1]
Heroin diacetylmorphine	DMDBWHY	Approved	Small molecular drug	[2]
Meticillin	DMIKHN0	Approved	Small molecular drug	[3]
Glypromate	DM0OX31	Phase 4	NA	[4]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 15 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AM-111	DM4E9PK	Phase 3	NA	[5]
Coprexa	DMA0WEK	Phase 3	Small molecular drug	[6]
IDAZOXAN HYDROCHLORIDE	DMSP0X8	Phase 3	Small molecular drug	[7]
ERYTHRITOL	DMATPN3	Phase 2/3	Small molecular drug	[8]
DT-1687	DMU2GP4	Phase 2	NA	[9]
LX-6171	DMCVCZ6	Phase 2	NA	[10]
PYM-50028	DMLQK6E	Phase 2	NA	[11]
SUVN-502	DMQD753	Phase 2	Small molecular drug	[12]
TPI-926	DM6NWJI	Phase 2	NA	[13]
TRAXOPRODIL MESYLATE	DM1ZQEN	Phase 2	Small molecular drug	[14]
Lu-AF11167	DM97V4W	Phase 1	NA	[15]
NBQX	DMPHZI5	Phase 1	Small molecular drug	[16]
OPC-14117	DMZWFKQ	Phase 1	Small molecular drug	[17]
R4996	DMSKHIC	Phase 1	NA	[18]
TEV-56192	DM41ZNM	Phase 1	Antibody	[19]
------------------------------------------------------------------------------------


⏷ Show the Full List of 15 Drug(s)

This Disease is Treated as An Indication in 18 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
LUBELUZOLE	DMFGMD9	Discontinued in Preregistration	Small molecular drug	[20]
Aloxistatin	DMGW07M	Discontinued in Phase 3	Small molecular drug	[21]
HER-801	DMSHB46	Discontinued in Phase 2	NA	[22]
RC-552	DMW2RBZ	Discontinued in Phase 2	NA	[23]
SIPATRIGINE	DMMQ4GC	Discontinued in Phase 2	Small molecular drug	[24]
TAK-218	DM7S69Q	Discontinued in Phase 2	NA	[25]
Tetramethylpyrazine	DMC0WNB	Discontinued in Phase 2	Small molecular drug	[26]
CGP-37849	DMOULQ4	Discontinued in Phase 1	Small molecular drug	[27]
Licostinel	DMMWCU3	Discontinued in Phase 1	Small molecular drug	[28]
Lu-AA38466	DMGUX5Y	Discontinued in Phase 1	NA	[29]
MX-4509	DMC4RK7	Discontinued in Phase 1	Small molecular drug	[30]
NSD-644	DMNL9DS	Discontinued in Phase 1	NA	[31]
U-104067F	DMC94D2	Discontinued in Phase 1	Small molecular drug	[32]
CLR-901	DM6LX8X	Terminated	NA	[34]
L-698532	DMO9HM7	Terminated	Small molecular drug	[35]
LY-367385	DM98POQ	Terminated	Small molecular drug	[36]
SDZ-SER-082	DMXHW91	Terminated	Small molecular drug	[37]
Seridopidine	DMTBWU1	Terminated	Small molecular drug	[38]
------------------------------------------------------------------------------------


⏷ Show the Full List of 18 Drug(s)

This Disease is Treated as An Indication in 2 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BIIR-777	DM2JOXF	Preclinical	NA	[33]
TEV-46000	DMYJA85	Preclinical	NA	[19]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 36 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
A-558693	DMN320E	Investigative	NA	[39]
ACPC	DMAZLWR	Investigative	NA	[40]
ARX-212	DMB7BZE	Investigative	NA	[41]
BQCA	DMSGIXK	Investigative	Small molecular drug	[42]
CL-301	DMW3RLB	Investigative	NA	[43]
CM-182	DM82NQG	Investigative	NA	[41]
CN-2097	DMJA8I4	Investigative	NA	[44]
CogniXan	DMKFJG5	Investigative	NA	[41]
CP-809101	DM3M1LA	Investigative	Small molecular drug	[45]
CPG23NEUR	DMX7D2G	Investigative	NA	[41]
FUB-130	DMCLSE0	Investigative	Small molecular drug	[46]
HBN-1	DMLNHZJ	Investigative	NA	[41]
HBN-2	DM5VDU2	Investigative	NA	[47]
HG-1336	DMCY6GL	Investigative	NA	[41]
JWB-1-84-1	DMXZ9RF	Investigative	NA	[48]
KI-0801	DM3A7EL	Investigative	NA	[41]
Lixte-1.2	DMG82HZ	Investigative	NA	[41]
NK-2210	DM192OD	Investigative	NA	[41]
PA-1637	DMUH203	Investigative	NA	[49]
PRX-12205	DML7TZ5	Investigative	NA	[41]
PRX-12239	DMTZPPK	Investigative	NA	[41]
PRX-12247	DMJ2T1M	Investigative	NA	[41]
PRX-12255	DM2V9VT	Investigative	NA	[41]
PRX-12256	DM6EGU9	Investigative	NA	[41]
PRX-12261	DMD5JBD	Investigative	NA	[41]
PRX-12266	DMX1NA0	Investigative	NA	[41]
PT-00311	DMB2SN7	Investigative	NA	[41]
Recombinant botulinum toxin	DMA6VCG	Investigative	NA	[48]
RTI-4229-982	DMG6TOA	Investigative	NA	[50]
SEM-606	DMDIZUT	Investigative	NA	[49]
SUVN-501	DMT8PKC	Investigative	NA	[51]
SUVN-507	DM2UMK8	Investigative	NA	[51]
SY-300	DMU9X3N	Investigative	NA	[41]
TA-111	DM472WM	Investigative	NA	[41]
TZ-111	DM7KKLM	Investigative	NA	[41]
UBP-551	DMTP31P	Investigative	NA	[41]
------------------------------------------------------------------------------------


⏷ Show the Full List of 36 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4942).
2	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3	Alpha-conotoxins. Int J Biochem Cell Biol. 2000 Oct;32(10):1017-28.
4	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021881)
5	ClinicalTrials.gov (NCT02235272) Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation. U.S. National Institutes of Health.
6	Copper binding by tetrathiomolybdate attenuates angiogenesis and tumor cell proliferation through the inhibition of superoxide dismutase 1. Clin Cancer Res. 2006 Aug 15;12(16):4974-82.
7	ClinicalTrials.gov (NCT00294944) The Effectiveness of Idazoxan in Treating TRD. U.S. National Institutes of Health.
8	ClinicalTrials.gov (NCT01062633) Effect of Erythritol and Xylitol on Dental Caries Prevention in Children. U.S. National Institutes of Health.
9	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 292).
10	ClinicalTrials.gov (NCT00691808) Study of LX6171 in Elderly Volunteers With Age Associated Memory Impairment. U.S. National Institutes of Health.
11	PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB J. 2008 Jul;22(7):2488-97.
12	Clinical pipeline report, company report or official report of Suven Life Sciences.
13	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021731)
14	ClinicalTrials.gov (NCT00163059) The Antidepressant Effects Of The NMDA Antagonist, CP-101,606, In Patients With MDD. U.S. National Institutes of Health.
15	ClinicalTrials.gov (NCT02199431) Study to Evaluate the Effect of a Known and Marketed Product, Itraconazole (Mycosis Treatment) on Lu AF11167 Entering the Body and Subsequently Elimination. The Studyis a Drug-drug Interaction Study in Healthy Volunteers.. U.S. National Institutes of Health.
16	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4264).
17	ClinicalTrials.gov (NCT00002148) Parallel Group, Placebo-Controlled, Tolerability, Safety, and Efficacy Study of OPC-14117 in HIV Dementia. U.S. National Institutes of Health.
18	Clinical pipeline report, company report or official report of Roche.
19	Clinical pipeline report, company report or official report of Teva Pharmaceutical
20	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005388)
21	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002441)
22	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800038058)
23	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011811)
24	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003904)
25	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800009120)
26	Determination of tetramethylpyrazine in animal serum and cerebrospinal fluid by high performance liquid chromatography. Se Pu. 2000 Jan;18(1):46-8.
27	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4154).
28	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003616)
29	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029333)
30	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020680)
31	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027571)
32	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006788)
33	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025224)
34	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023986)
35	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006620)
36	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1379).
37	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 195).
38	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800011877)
39	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2336).
40	1-Aminocyclopropane carboxylic acid (ACPC) prevents mu and delta opioid tolerance. Life Sci. 1994;55(18):1393-8.
41	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
42	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5436).
43	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 969).
44	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 457).
45	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 8).
46	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1260).
47	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 309).
48	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 467).
49	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
50	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 293).
51	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 11).